PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Infectious Diseases, School of Immunology & Microbial Sciences, King\'s College London, London, United Kingdom.\', \'Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy\'s and St Thomas\' NHS Foundation Trust, London, United Kingdom.\', \'Centre for Inflammation Biology and Cancer Immunology (CIBCI), Dept of Inflammation Biology, School of Immunology & Microbial Sciences, King\'s College London, London, United Kingdom.\', \'Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King\'s College London, London, United Kingdom.\', \'MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.\', \'Division of Infection and Immunity, University College London (UCL), London, United Kingdom.\', \'Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.ppat.1008817
?:doi
?:hasPublicationType
?:journal
  • PLoS pathogens
is ?:pmid of
?:pmid
?:pmid
  • 32970782
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 4.006
?:rankingScore_hIndex
  • 154
?:title
  • Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all